drugset / Trial / NCT00663897

Lansoprazole Versus Mosapride for Functional Dyspepsia

NCT00663897

RandomizedParallel-groupOpen-labelTreatment

Summary

Functional dyspepsia is a common symptom complex with significant impact on quality of life. There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study has two aims: * first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a prokinetic agent) for functional dyspepsia * second is to investigate whether different subgroups of functional dyspepsia (e.g., epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI and prokinetic agent.

Timeline

Start
2008-05
Primary completion
2009-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg
Comparator Mosapride Small molecule 5 mg

Indications